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Hearing loss has been rarely reported in Takayasu’s arteritis, may present as Sudden Sensorineural Hearing Loss, and usually
responds well to corticosteroid therapy. Hyperbaric Oxygen Therapy is commonly used as a supplementary treatment to
corticosteroids for Sudden Sensorineural Hearing Loss. We present the case of a 36-year-old woman with Takayasu’s arteritis who
had two episodes of sudden hearing loss involving one ear at a time with an 11-month delay between each episode. During the
first episode, the patient was treated with high-dose intramuscular corticosteroids with a temporary improvement of auditory
threshold that deteriorated 14 days after cessation of therapy. In the second episode, Hyperbaric Oxygen Therapy was associated
with corticosteroids, with improvements in both ears, including the one that was unresponsive in the long term to previous
pharmacologic therapy. In this case, Hyperbaric OxygenTherapy could have acted synergically with corticosteroids playing a role
in hearing restoration.
1. Introduction
Takayasu’s arteritis (TA), also known as aortitis syndrome, is
a vasculitis more prevalent in women of reproductive age that
mainly affects large elastic arteries with symptoms caused by
organ ischemia, aneurysm formation, and inflammation [1].
Clinical features usually reflect limb or organ ischemia that
follow gradual stenosis of the involved arteries [2, 3].
Hearing loss (HL) has been rarely reported in patients
with TA.HL can be stable or fluctuating, involvesmainly high
frequencies, may present as a Sudden Sensorineural Hearing
Loss (SSHL), and usually responds well to corticosteroid
therapy. HL in TA is often diagnosed as idiopathic SSHL.
Hyperbaric Oxygen Therapy (HBOT) involves breathing
pure oxygen and is commonly used as a supplementary treat-
ment to corticosteroid treatment for SSHL by increasing the
supply of oxygen to the inner ear and brain. Current research
supports the role of HBOT in SSHL if used within two weeks
from the onset of HL, while there is no evidence that HBOT
can help after that time [4, 5]. A recent paper on 167 SSHL
cases reported that HBOT, if performed appropriately, could
be able to improve hearing in many cases unresponsive to
initial corticosteroid therapy [6].
There are no studies in the literature that report the use
of HBOT for the treatment of HL in patients with TA. The
aim of this study is to present a case of a TA patient with two
episodes of SSHL which occurred at different times treated
with HBOT in addition to corticosteroid therapy.
2. Case Report
A 36-year-old woman affected by TA was treated in the Oto-
laryngology Department of the Policlinico Umberto I Hos-
pital, Sapienza University of Rome, following two episodes
of sudden hearing loss with continuous low-pitch tinnitus
without vertigo and associated neurovegetative symptoms.
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Figure 1: Magnetic Resonance Angiography (MRA) showing nar-
rowing of the common carotid arteries bilaterally and the left
subclavian artery (large arrowhead). Vertebral and intracranial
carotid arteries were normal bilaterally.
Thefirst episode occurred inApril 2016 and involved the right
ear; the second occurred in March 2017 and involved the left
ear.
Diagnosis of TA was posed in 2001 following the cri-
teria of the American College of Rheumatology [7] and
was based on the onset of asthenia, sideropenic anemia,
asymmetry of radial arterial pulsation, and amaurosis fugax.
Laboratory tests revealed increased inflammatory markers
(erythrocyte sedimentation rate, C-reactive protein) and
epiaortic ultrasound showed a significant stenosis of the left
subclavian artery and right common carotid artery and a
nonsignificant stenosis of abdominal aorta, renal artery, and
mesenteric artery. Magnetic Resonance Angiography (MRA)
confirmed diagnosis (Figure 1). High-dose steroid therapy
(prednisone 50mg/day) and methotrexate (15mg/day) were
administered and a progressive stabilization of clinical and
laboratory findings was obtained in the following 15 years.
Maintenance steroid therapywas initiated (0.3mg/kgmethyl-
prednisolone/day) and continued until present time.
After admission following the first episode of SSHL in
April 2016, patient underwent a complete ENT examina-
tion with otoscopy, Pure Tone Audiometry (PTA), Immit-
tance test, Auditory Brainstem Response (ABR), Distortion-
Product Otoacoustic Emissions (DPOAE), MRA, and Ultra-
sound.
MRA showed a significant stenosis of the left subcla-
vian artery and common carotid arteries bilaterally and
a nonsignificant stenosis of abdominal aorta, renal artery,
and mesenteric artery. Volume-rendered reconstructions
from MRA are shown in Figure 2. Ultrasound showed
no vascular changes in the epiaortic vessels compared to
the previous examinations. Positron Emission Tomography
showedworsening of the vascular inflammatory state, mainly
involving the common, external, and internal carotid arteries
and vertebral arteries. PTA showed moderate sensorineural
hearing loss in the right ear with an average PTA threshold of
49.54 dBHL and normal hearing in the left side (Figure 3(a)).
Weber test was lateralized to the left at all frequencies.
Immittance test was within normal range. ABR revealed in
the right ear the absence of the 1st wave and an increased
hearing threshold (80 dB).
The patient was treated with high-dose intramuscular
steroid therapy (betamethasone 8mg/day for 10 days), in
addition to ongoing maintenance steroid therapy. Her audi-
bility significantly improved three days after the beginning
of treatment (average threshold in the right ear: 23.2 dBHL)
(Figure 3(b)) but deteriorated close to previous level (average
threshold in the right ear: 54.09 dBHL) 14 days after cessation
of therapy, as shown in Figure 3(c). Hearing remained stable
over the following months.
Several months later, in March 2017, the patient was
admitted to our Department complaining of a new episode
of SSHL which occurred in the left ear. PTA confirmed
a new onset SSHL in the left ear, with an average PTA
threshold of 38.18 dBHL; threshold in the right ear was
unmodified compared to the exam performed 14 days after
cessation of previous treatment (56.09 dBHL) (Figure 4(a)).
The patient was already undergoing maintenance steroid
therapy (0.3mg/kg methylprednisolone/day). The patient
was treated with high-dose intramuscular steroid therapy
(betamethasone 8mg/day for 10 days) accompanied by 16
sessions of HBOT (1/day, 6 days/week) started two days
after the SSHL episode. PTA recorded 2 weeks after SSHL
onset showed a significant improvement of HL in the left
ear (average: 22.72 dBHL) but also in the right ear (average:
30.45 dBHL) (Figure 4(b)). Hearing thresholds in both ears
remained stable over the following twomonths (Figure 4(c)).
3. Discussion
3.1. Takayasu’s Arteritis and Hearing Loss. In this patient,
hearing loss presented as SSHL in two episodes involving one
ear at a time, with an 11-month delay between each other and
with different paths of hearing recovery. The first episode,
occurring in the right ear, was treated with corticosteroid
therapy only and showed hearing improvement during ther-
apy that deteriorated soon after cessation of the therapy. The
second (left ear) was treated with corticosteroid therapy and
HBOT; this therapy induced a significant improvement in the
affected ear and, interestingly, also in the contralateral side. In
addition, hearing thresholds in both ears did not change for
a period of two months after completion of the therapy.
There are only a few cases in the literature that reported an
association of TA with HL [8–10]. HL in TA may present as
SSHL and is usually diagnosed and treated as an idiopathic
SSHL. However, HL associated with TA arteritis is often
progressive and fluctuates during treatment; it may have a
good response to corticosteroid therapy but may also persist
despite corticosteroid therapy [11]. A progressive fluctuating
bilateral asymmetric SNHL that develops over several weeks
to months is a common finding in autoimmune disorders
[12, 13].
The etiology of hearing deficits in TA is unknown [14,
15]. A connection with the autoimmune pathophysiology of
TA has been hypothesized due to the elevation of serum
immune complexes in TA that deposit in the inner ear [14],
hypercoagulability in response to the arterial disease [16],
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Figure 2: Volume-rendered reconstructions from Magnetic Resonance Angiography examination showing diffuse narrowing of the left
subclavian artery (a) and common carotid arteries bilaterally (b). Normal caliber was found for intracranial arteries ((c)-(d)).
and the good response to anti-inflammatory therapy with
corticosteroids. Although TA involves medium and large
caliber arteries, Maruyoshi speculated that HL in TA could
have a vascular background based on reversible circulatory
disturbances due to vasculitis and/or some autoimmune
pathogenesis in the inner ear, especially in hair cells [11].
3.2. Effects of Steroid Therapy on Hearing Loss in Takayasu’s
Arteritis. Many authors confirmed the beneficial effects of
steroid administration onHL in TA; therefore steroids should
be used as first-line therapy in this condition [9, 14, 15].
However, steroid therapymust be administered chronically to
control TA symptoms; the interruption of steroid treatment
has been reported to exacerbate the hearing deficit [15].
Intratympanic injection of steroids may be an alternative
treatment to systemic therapy.
One of the first authors to report HL in TA was Kanzaki
in 1981, who described a beneficial effect of prednisolone [14].
Murofushi et al. reported a case of a 44-year-old woman with
fluctuating sensorineuralHL in the high frequencies suffering
from TA who was treated with intratympanic injection of
dexamethasone at the time of worsening of hearing [17].
Kunihiro et al. reported 5 cases of TA patients with HL
in which the degree of hearing loss correlated well with
the erythrocyte sedimentation rate. All patients responded
well to corticosteroid therapy, supporting the hypothesis that
inner ear manifestations of the disease arose from similar
mechanisms as those of systemic inflammatory process [9]. In
2005Maruyoshi et al. reported a case of a 49-year-old woman
with TA who experienced sudden hearing loss five years
before diagnosis of TA, treated with systemic corticosteroid
therapy. After cessation of the therapy, HL worsened. After
TA diagnosis, the patient was treated with daily prednisolone
(0.3mg/kg/day) with significant improvement in hearing
threshold in the right ear, while no changes were found in the
contralateral ear [11].
TA has been reported to be associated with Cogan’s
syndrome [18], a rare disorder of unknown origin charac-
terized by inflammatory eye disease (74% of the cases) with
interstitial keratitis and vestibuloauditory symptoms [19].
In this case, ocular and vestibular symptoms were never
reported despite the long history of TA in the patient; further-
more, auditory involvement is always severe and frequently
progresses within several hours or days to total deafness [20].
Therefore, Cogan’s syndrome was ruled out in this case.
3.3. Possible Role of Hyperbaric Oxygen Therapy in Treating
Hearing Loss in Takayasu’s Arteritis. In this patient, we found
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Figure 3: PTA in our patient recorded one, three, and 14 days after onset of Sudden Sensorineural Hearing Loss in the right ear (first episode).
(a) Pure Tone Audiometry recorded one day after hearing loss onset showing a moderate sensorineural hearing loss in the right ear with an
average auditory threshold of 49.54 dBHL and normal hearing threshold in the left side. (b) Pure Tone Audiometry recorded three days
after hearing loss onset; hearing in the right side significantly improved (average threshold: 23.2 dBHL). (c) When recording Pure Tone
Audiometry 14 days after sudden hearing loss onset, and 4 days after cessation of high-dose corticosteroid therapy, hearing in the right ear
returned to previous levels with an average threshold of 54.09 dBHL.
a significant improvement of hearing threshold in both
ears with HBOT performed in conjunction with high-dose
corticosteroid therapy after the second episode of SSHL.
Interestingly, HBOT induced a rapid increase in hearing
threshold in both ears, more marked in the right ear in
which hearing significantly decreased 11 months prior to
therapy, and had shown to be unresponsive in the long term
to steroid therapy performed immediately after HL onset. A
possible explanation of this finding could be attributed to
the vascular effects of hyperbaric therapy, such as enhancing
oxygen, glucose, and adenosine triphosphate delivery to
ischemic tissues, and vasodilation. However, the selectivity
of TA for medium and large arteries raises questions about
effectiveness of such therapy in small vessels such as in
the inner ear; our findings could support the involvement
of inner ear microcirculation in HL presenting in TA
patients.
Although the exclusive role of HBOT in this patient
cannot be documented since it has been performed in
addition to steroid therapy and no long term follow-up
is available, the significant improvement on HL in both
sides, including the one in which HL presented over 11
months prior to HBOT, is certainly worth discussion. In
this case, HBOT could have worked synergically with
steroid therapy and amplified treatment results in the long
term.
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Figure 4: Pure Tone Audiometry recorded one, 14, and 60 days after onset of sudden hearing loss in the left ear (second episode). (a) Pure
Tone Audiometry confirmed hearing loss in the left ear, with an average threshold of 38.18 dBHL; threshold in the right ear was unmodified
compared to the exam performed 14 days after cessation of previous treatment (56.09 dBHL); (b) Pure Tone Audiometry recorded 14 days
after hearing loss onset showed a significant improvement of hearing loss in the left ear (average: 22.72 dBHL) but also in the right ear (average:
30.45 dBHL); (c) Audiometry 60 days after left sudden hearing loss onset showed no significant differences compared to previous exam, with
preserved hearing threshold in both ears.
Current findings certainly require further studies on
larger samples; however, they may suggest, when no individ-
ual contraindication is present, the use of HBOT even several
months after HL onset in patients with a diagnosis of TA.
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